Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

Retro-1-Oligonucleotide Conjugates. Synthesis and Biological Evaluation.

Agramunt J, Pedroso E, Kreda SM, Juliano RL, Grandas A.

Molecules. 2019 Feb 6;24(3). pii: E579. doi: 10.3390/molecules24030579.

2.

Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Don't.

Juliano RL.

Nucleic Acid Ther. 2018 Jun;28(3):166-177. doi: 10.1089/nat.2018.0727. Epub 2018 Apr 30. Review.

3.

RGD Conjugated Dendritic Polylysine for Cellular Delivery of Antisense Oligonucleotide.

Le TD, Nakagawa O, Fisher M, Juliano RL, Yoo H.

J Nanosci Nanotechnol. 2017 Apr;17(4):2353-357.

PMID:
29641161
4.

Structure-activity relationships and cellular mechanism of action of small molecules that enhance the delivery of oligonucleotides.

Juliano RL, Wang L, Tavares F, Brown EG, James L, Ariyarathna Y, Ming X, Mao C, Suto M.

Nucleic Acids Res. 2018 Feb 28;46(4):1601-1613. doi: 10.1093/nar/gkx1320.

5.

A Novel Family of Small Molecules that Enhance the Intracellular Delivery and Pharmacological Effectiveness of Antisense and Splice Switching Oligonucleotides.

Wang L, Ariyarathna Y, Ming X, Yang B, James LI, Kreda SM, Porter M, Janzen W, Juliano RL.

ACS Chem Biol. 2017 Aug 18;12(8):1999-2007. doi: 10.1021/acschembio.7b00242. Epub 2017 Jul 14.

6.

The delivery of therapeutic oligonucleotides.

Juliano RL.

Nucleic Acids Res. 2016 Aug 19;44(14):6518-48. doi: 10.1093/nar/gkw236. Epub 2016 Apr 15. Review.

7.

Recent Developments in Oligonucleotide Based Therapeutics. Preface.

Juliano RL, Ming X.

Adv Drug Deliv Rev. 2015 Jun 29;87:1-2. doi: 10.1016/j.addr.2015.06.010. No abstract available.

PMID:
26175452
8.

DNA Three-Way Junctions Stabilized by Hydrophobic Interactions for Creation of Functional Nanostructures.

Laing BM, Juliano RL.

Chembiochem. 2015 Jun 15;16(9):1284-7. doi: 10.1002/cbic.201500034. Epub 2015 May 7.

PMID:
25953428
9.

Cellular uptake and intracellular trafficking of oligonucleotides.

Juliano RL, Carver K.

Adv Drug Deliv Rev. 2015 Jun 29;87:35-45. doi: 10.1016/j.addr.2015.04.005. Epub 2015 Apr 14. Review.

10.

Conditional control of alternative splicing through light-triggered splice-switching oligonucleotides.

Hemphill J, Liu Q, Uprety R, Samanta S, Tsang M, Juliano RL, Deiters A.

J Am Chem Soc. 2015 Mar 18;137(10):3656-62. doi: 10.1021/jacs.5b00580. Epub 2015 Mar 3.

11.

High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides.

Yang B, Ming X, Cao C, Laing B, Yuan A, Porter MA, Hull-Ryde EA, Maddry J, Suto M, Janzen WP, Juliano RL.

Nucleic Acids Res. 2015 Feb 27;43(4):1987-96. doi: 10.1093/nar/gkv060. Epub 2015 Feb 6.

12.

Tumor cell-targeted delivery of nanoconjugated oligonucleotides in composite spheroids.

Carver K, Ming X, Juliano RL.

Nucleic Acid Ther. 2014 Dec;24(6):413-9. doi: 10.1089/nat.2014.0493.

13.

Multicellular tumor spheroids as a model for assessing delivery of oligonucleotides in three dimensions.

Carver K, Ming X, Juliano RL.

Mol Ther Nucleic Acids. 2014 Mar 11;3:e153. doi: 10.1038/mtna.2014.5.

14.

Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology.

Juliano RL, Ming X, Carver K, Laing B.

Nucleic Acid Ther. 2014 Apr;24(2):101-13. doi: 10.1089/nat.2013.0463. Epub 2014 Jan 2. Review.

15.

Covalent conjugation of oligonucleotides with cell-targeting ligands.

Alam MR, Ming X, Nakagawa O, Jin J, Juliano RL.

Bioorg Med Chem. 2013 Oct 15;21(20):6217-23. doi: 10.1016/j.bmc.2013.05.037. Epub 2013 Jun 1.

16.

The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides.

Ming X, Carver K, Fisher M, Noel R, Cintrat JC, Gillet D, Barbier J, Cao C, Bauman J, Juliano RL.

Nucleic Acids Res. 2013 Apr 1;41(6):3673-87. doi: 10.1093/nar/gkt066. Epub 2013 Feb 8.

17.

Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides.

Juliano RL, Carver K, Cao C, Ming X.

J Drug Target. 2013 Jan;21(1):27-43. doi: 10.3109/1061186X.2012.740674. Epub 2012 Nov 19. Review.

18.

Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells.

Kotula JW, Pratico ED, Ming X, Nakagawa O, Juliano RL, Sullenger BA.

Nucleic Acid Ther. 2012 Jun;22(3):187-95. doi: 10.1089/nat.2012.0347.

19.

The chemistry and biology of oligonucleotide conjugates.

Juliano RL, Ming X, Nakagawa O.

Acc Chem Res. 2012 Jul 17;45(7):1067-76. doi: 10.1021/ar2002123. Epub 2012 Feb 21.

20.

Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides.

Juliano RL, Ming X, Nakagawa O.

Bioconjug Chem. 2012 Feb 15;23(2):147-57. doi: 10.1021/bc200377d. Epub 2011 Oct 27. Review.

21.

A molecular umbrella approach to the intracellular delivery of small interfering RNA.

Cline LL, Janout V, Fisher M, Juliano RL, Regen SL.

Bioconjug Chem. 2011 Nov 16;22(11):2210-6. doi: 10.1021/bc200347x. Epub 2011 Oct 13.

22.

Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA.

Alam MR, Ming X, Fisher M, Lackey JG, Rajeev KG, Manoharan M, Juliano RL.

Bioconjug Chem. 2011 Aug 17;22(8):1673-81. doi: 10.1021/bc200235q. Epub 2011 Jul 20.

23.

Unconventional internalization mechanisms underlying functional delivery of antisense oligonucleotides via cationic lipoplexes and polyplexes.

Ming X, Sato K, Juliano RL.

J Control Release. 2011 Jul 15;153(1):83-92. doi: 10.1016/j.jconrel.2011.04.029. Epub 2011 May 4.

24.

Integrin targeted delivery of gene therapeutics.

Juliano RL, Ming X, Nakagawa O, Xu R, Yoo H.

Theranostics. 2011 Mar 2;1:211-9.

25.

Targeted albumin-based nanoparticles for delivery of amphipathic drugs.

Xu R, Fisher M, Juliano RL.

Bioconjug Chem. 2011 May 18;22(5):870-8. doi: 10.1021/bc1002295. Epub 2011 Apr 19.

26.

The Carolina Center of Cancer Nanotechnology Excellence: past accomplishments and future perspectives.

Juliano RL, Sunnarborg S, DeSimone J, Haroon Z.

Nanomedicine (Lond). 2011 Jan;6(1):19-24. doi: 10.2217/nnm.10.142.

27.

Overbuilding: doctoral degree surplus.

Juliano RL.

Science. 2010 Nov 19;330(6007):1045. doi: 10.1126/science.330.6007.1045-a. No abstract available.

PMID:
21097919
28.

Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor.

Ming X, Alam MR, Fisher M, Yan Y, Chen X, Juliano RL.

Nucleic Acids Res. 2010 Oct;38(19):6567-76. doi: 10.1093/nar/gkq534. Epub 2010 Jun 15.

29.

Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands.

Nakagawa O, Ming X, Huang L, Juliano RL.

J Am Chem Soc. 2010 Jul 7;132(26):8848-9. doi: 10.1021/ja102635c.

30.

Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents.

Juliano RL, Alam R, Dixit V, Kang HM.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 May-Jun;1(3):324-35. doi: 10.1002/wnan.4. Review.

PMID:
20049800
31.

The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking.

Alam MR, Ming X, Dixit V, Fisher M, Chen X, Juliano RL.

Oligonucleotides. 2010 Apr;20(2):103-9. doi: 10.1089/oli.2009.0211.

32.

Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf.

Fisher M, Abramov M, Van Aerschot A, Rozenski J, Dixit V, Juliano RL, Herdewijn P.

Eur J Pharmacol. 2009 Mar 15;606(1-3):38-44. doi: 10.1016/j.ejphar.2009.01.030. Epub 2009 Jan 30.

33.

Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility.

Kim TY, Vigil D, Der CJ, Juliano RL.

Cancer Metastasis Rev. 2009 Jun;28(1-2):77-83. doi: 10.1007/s10555-008-9167-2. Review.

34.

Cellular delivery and biological activity of antisense oligonucleotides conjugated to a targeted protein carrier.

Kang H, Alam MR, Dixit V, Fisher M, Juliano RL.

Bioconjug Chem. 2008 Nov 19;19(11):2182-8. doi: 10.1021/bc800270w.

35.

Effects of structure of Rho GTPase-activating protein DLC-1 on cell morphology and migration.

Kim TY, Healy KD, Der CJ, Sciaky N, Bang YJ, Juliano RL.

J Biol Chem. 2008 Nov 21;283(47):32762-70. doi: 10.1074/jbc.M800617200. Epub 2008 Sep 11.

36.

Selective killing of Smad4-negative tumor cells via a designed repressor strategy.

Dixit V, Juliano RL.

Mol Pharmacol. 2008 Jul;74(1):289-97. doi: 10.1124/mol.108.046953. Epub 2008 Apr 21.

37.

Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis.

Alam MR, Dixit V, Kang H, Li ZB, Chen X, Trejo J, Fisher M, Juliano RL.

Nucleic Acids Res. 2008 May;36(8):2764-76. doi: 10.1093/nar/gkn115. Epub 2008 Mar 26.

38.

2'-O-hydroxyalkoxymethylribonucleosides and their incorporation into oligoribonucleotides.

Mikhailov SN, Bobkov GV, Brilliantov KV, Rozenski J, Van Aerschot A, Herdewijn P, Fisher MH, Juliano RL.

Nucleosides Nucleotides Nucleic Acids. 2007;26(10-12):1509-12.

39.

DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms.

Healy KD, Hodgson L, Kim TY, Shutes A, Maddileti S, Juliano RL, Hahn KM, Harden TK, Bang YJ, Der CJ.

Mol Carcinog. 2008 May;47(5):326-37.

40.

Structural characterization and biological evaluation of small interfering RNAs containing cyclohexenyl nucleosides.

Nauwelaerts K, Fisher M, Froeyen M, Lescrinier E, Aerschot AV, Xu D, DeLong R, Kang H, Juliano RL, Herdewijn P.

J Am Chem Soc. 2007 Aug 1;129(30):9340-8. Epub 2007 Jul 6.

PMID:
17616127
41.

Inhibition of MDR1 expression with altritol-modified siRNAs.

Fisher M, Abramov M, Van Aerschot A, Xu D, Juliano RL, Herdewijn P.

Nucleic Acids Res. 2007;35(4):1064-74. Epub 2007 Jan 30.

42.

Intracellular delivery of oligonucleotide conjugates and dendrimer complexes.

Juliano RL.

Ann N Y Acad Sci. 2006 Oct;1082:18-26.

PMID:
17145920
43.

Clinging to life: cell to matrix adhesion and cell survival.

Reddig PJ, Juliano RL.

Cancer Metastasis Rev. 2005 Sep;24(3):425-39. Review.

PMID:
16258730
44.

Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides.

Kang H, DeLong R, Fisher MH, Juliano RL.

Pharm Res. 2005 Dec;22(12):2099-106. Epub 2005 Oct 1.

PMID:
16184444
45.

Epigenetic modulation of gene expression in mammalian cells.

Xu D, Juliano RL.

Crit Rev Eukaryot Gene Expr. 2005;15(2):93-101. Review.

PMID:
16022630
46.

Regulation of p21-activated kinase-independent Rac1 signal transduction by nischarin.

Reddig PJ, Xu D, Juliano RL.

J Biol Chem. 2005 Sep 2;280(35):30994-1002. Epub 2005 Jul 7.

47.

Epigenetic manipulation of gene expression: a toolkit for cell biologists.

Juliano RL, Dixit VR, Kang H, Kim TY, Miyamoto Y, Xu D.

J Cell Biol. 2005 Jun 20;169(6):847-57. Review.

49.

Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA.

Juliano RL.

Curr Opin Mol Ther. 2005 Apr;7(2):132-6. Review.

PMID:
15844620
50.

Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector.

Xu D, McCarty D, Fernandes A, Fisher M, Samulski RJ, Juliano RL.

Mol Ther. 2005 Apr;11(4):523-30.

Supplemental Content

Loading ...
Support Center